Abstract:Abstract Neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein Ab disease, and autoimmune myasthenia gravis (MG) are autoantibody-mediated neurologic conditions where autoantibodies can induce Ab-dependent cellular cytotoxicity (ADCC), a NK cell–mediated effector function. However, whether ADCC is a pathogenic mechanism in patients with these conditions has not been confirmed. We sought to characterize circulatory NK cells using functional assays, phenotyping, and transcriptomics to elucidate their role in pathology. NK cells from NMOSD patients and MG patients with elevated disease burden exhibited reduced ADCC and CD56dimCD16hi NK cells, along with an elevated frequency of CD56dimCD16dim/− NK cells. We determined that ADCC induces a similar phenotypic shift in vitro. Bulk RNA sequencing distinguished the CD56dimCD16dim/− population from the canonical CD56dimCD16hi cytotoxic and CD56hiCD16− immunomodulatory subsets, as well as CD56hiCD16+ NK cells. Multiparameter immunophenotyping of NK cell markers, functional proteins, and receptors similarly showed that the CD56dimCD16dim/− subset exhibits a unique profile while still maintaining expression of characteristic NK markers CD56, CD94, and NKp44. Notably, expression of perforin and granzyme is reduced in comparison with CD56dimCD16hi NK cells. Moreover, they exhibit elevated trogocytosis capability, HLA-DR expression, and many chemokine receptors, including CCR7. In contrast with NMOSD and MG, myelin oligodendrocyte glycoprotein Ab disease NK cells did not exhibit functional, phenotypic, or transcriptomic perturbations. In summary, CD56dimCD16dim/− NK cells are a distinct peripheral blood immune cell population in humans elevated upon prior cytotoxic activity by the CD56dimCD16hi NK cell subset. The elevation of this subset in NMOSD and MG patients suggests prior ADCC activity.

The role of CD56bright NK cells in neurodegenerative disorders

Natural killer cells in the central nervous system

CD4+ T-Cell Senescence in Neurodegenerative Disease: Pathogenesis and Potential Therapeutic Targets

NKT Cells in Neurological Diseases

Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients

The role of the CD8+ T cell compartment in ageing and neurodegenerative disorders

Frontiers of Neurodegenerative Disease Treatment: Targeting Immune Cells in Brain Border Regions

A Noncanonical CD56dimCD16dim/− NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases

Myeloid antigen-presenting cells in neurodegenerative diseases: a focus on classical and non-classical MHC molecules

The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases

Pathological Role of Natural Killer Cells in Parkinson's Disease: A Systematic Review

Roles of Microglia in Neurodegenerative Diseases

More than microglia: myeloid cells and biomarkers in neurodegeneration

Emergence of the brain-border immune niches and their contribution to the development of neurodegenerative diseases

Single-cell profiling reveals periventricular CD56bright NK cell accumulation in multiple sclerosis

Frontiers of neurodegeneration diseases treatment: Targeting immune cells in brain border regions

Emerging T cell immunoregulatory mechanisms in multiple sclerosis and Alzheimer's disease

Role of Microglia in Neurological Disorders and Their Potentials As a Therapeutic Target

Human NK cells responses are enhanced by CD56 engagement

T Cells: A Growing Universe of Roles in Neurodegenerative Diseases

[Research Progress of CD4+T Cells-mediated Regulation of Neuroinflammation Involved in Neurodegenerative Diseases]